Recent advances for FLAP inhibitors

Bioorg Med Chem Lett. 2015 Jul 1;25(13):2607-12. doi: 10.1016/j.bmcl.2015.04.090. Epub 2015 May 6.

Abstract

A number of FLAP inhibitors have been progressed to clinical trials for respiratory and other inflammatory indications but so far no drug has reached the market. With this Digest we assess the opportunity to develop FLAP inhibitors for indications beyond respiratory disease, and in particular for atherosclerotic cardiovascular disease. We also show how recently disclosed FLAP inhibitors have structurally evolved from the first generation FLAP inhibitors paving the way for new compound classes.

Keywords: 5-LO; Cardiovascular; FLAP; Inflammatory; Leukotrienes.

Publication types

  • Review

MeSH terms

  • 5-Lipoxygenase-Activating Protein Inhibitors / chemistry*
  • 5-Lipoxygenase-Activating Protein Inhibitors / pharmacology*
  • Animals
  • Asthma / drug therapy
  • Atherosclerosis / drug therapy
  • Drug Design
  • Drug Discovery
  • Humans
  • Inflammation / drug therapy
  • Leukotrienes / metabolism
  • Molecular Structure

Substances

  • 5-Lipoxygenase-Activating Protein Inhibitors
  • Leukotrienes